Last reviewed · How we verify
Peg-Interferon Alpha-2A
At a glance
| Generic name | Peg-Interferon Alpha-2A |
|---|---|
| Also known as | Pegasys, Peg-IFN-Alpha-2A |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Pegasys® in Patients With Myeloproliferative Diseases (PHASE2)
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) (PHASE2)
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peg-Interferon Alpha-2A CI brief — competitive landscape report
- Peg-Interferon Alpha-2A updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI